Advertisement

Picture EBD Group BIO-Europe Spring 2025 Milan to 28 Feb 650x100px
Document › Details

Taysha Gene Therapies, Inc.. (4/5/21). "Press Release: Taysha Gene Therapies to Participate in Upcoming April Investor Healthcare Conferences". Dallas, TX.

Organisations Organisation Taysha Gene Therapies Inc. (Nasdaq: TSHA)
  Organisation 2 Chardan Capital Markets LLC
Products Product Needham & Company 20th Annual Healthcare Conference 2021 DIGITAL
  Product 2 adeno-associated viral vector (AAV vector)
Persons Person Session, RA, II (Taysha Gene Therapies 202008 CEO + Founder)
  Person 2 Hawley, Carolyn (Canale Communications 202008)
     


> 20th Annual Needham Virtual Healthcare Conference on Monday, April 12, 2021 at 10:15 am ET

> Chardan 5th Annual Manufacturing Summit on Monday, April 26, 2021 at 1:00 pm ET


Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced its participation in virtual fireside chats for the 20th Annual Needham Virtual Healthcare Conference and the Chardan 5th Annual Manufacturing Summit.


Conferences Details:

Event: 20th Annual Needham Virtual Healthcare Conference
Date: Monday, April 12, 2021
Time: 10:15 am ET
Format: Fireside chat
Participants: RA Session II, President, Founder and CEO

Event: Chardan 5th Annual Manufacturing Summit
Date: Monday, April 26, 2021
Time: 1:00 pm ET
Format: Fireside chat
Participants:
RA Session II, President, Founder and CEO
Fred Porter, Ph.D., Chief Technical Officer
Greg Gara, Senior Vice President of Manufacturing

Webcasts for these conferences will be available in the “Events & Media” section of the Taysha corporate website at https://ir.tayshagtx.com/news-events/events-presentations. Archived versions of the webcasts will be available on the website for 60 days.


About Taysha Gene Therapies

Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients’ lives. More information is available at www.tayshagtx.com.

Contacts

Company Contact:
Kimberly Lee, D.O.
SVP, Corporate Communications and Investor Relations
Taysha Gene Therapies
[email protected]

Media Contact:
Carolyn Hawley
Canale Communications
[email protected]

   
Record changed: 2023-06-05

Advertisement

Picture EBD Group BIO-Europe Spring 2025 Milan to 28 Feb 650x200px

More documents for Taysha Gene Therapies Inc. (Nasdaq: TSHA)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Kenes Exhibitions Biomed Israel 2025 Tel Aviv 650x300px




» top